We recently had a chance to interview one of the portfolio managers for the Ranger Equity Bear ETF (NYSEMKT: HDGE), which is an actively managed short selling exchange-traded fund. It acts like a short selling hedge fund but with instant market liquidity features that an ETF structure provides. The ETF’s major short selling position in shares of International Business Machines Corp. (NYSE: IBM) was what really piqued our interest. Investors did well who decided to move out of IBM as Big Blue’s stock price has managed to fall by more than $11 per share since then. It turns out that the team here remains a short seller of IBM, and this is indirectly a bet against Warren Buffett.
The reason we are revisiting this is not just to offer a cheerleading session for a short seller, but because IBM is extremely important to the market. IBM is not just a DJIA component. It is the largest DJIA component by far because of its share price being so high and the DJIA being a price-weighted stock index rather than a market cap-weighted index. Another reason that IBM is of such interest to us on a slow August day is that it is one of the cheapest Warren Buffett stocks for value investors if you use the implied upside expected by Wall Street analysts. IBM has now hit a new 52-week low, but the consensus analyst price target implies something to the tune of 17%.
Top Prefered Stocks To Buy Right Now: China Automotive Systems Inc.(CAAS)
China Automotive Systems, Inc., through its interests in Sino-foreign joint ventures, engages in the manufacture and sale of power steering systems and other component parts for the automotive industry in the People?s Republic of China. It offers a range of steering system parts for passenger automobiles and commercial vehicles. The company provides 4 separate series, 307 models of power steering, including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. China Automotive Systems, Inc. was founded in 2003 and is headquartered in Jing Zhou City, the People?s Republic of China.
Advisors' Opinion:- [By Richard Schmidt]
China Automotive Systems (CAAS), which makes auto systems and components, reported record-high net sales for the third quarter. The report excited investors, who bid the stock up about 30% for the month.
- [By Richard Schmidt]
We admittedly bought into China Automotive Systems (CAAS) too soon. The stock is still down from our original recommendation price, but the future looks very bright.
Top Prefered Stocks To Buy Right Now: AspenBio Pharma Inc.(APPY)
AspenBio Pharma, Inc. operates as an emerging biomedical company focused on obtaining the United States FDA clearance for its lead product, AppyScore. Its research and development activities primarily focus on a human appendicitis blood-based test. The company?s lead product candidate, AppyScore, is a blood-based diagnostic test to help physicians manage patients who enter emergency rooms complaining of abdominal pain and suspected of having acute appendicitis. It is also developing animal healthcare products focusing on reproduction. The company was formerly known as AspenBio, Inc. and changed its name to AspenBio Pharma, Inc. on September 26, 2005. AspenBio Pharma, Inc. was founded in 2000 and is based in Castle Rock, Colorado.
Advisors' Opinion:- [By James E. Brumley]
To tell the truth, I'm not the least bit surprised that I'm chiming in on Venaxis Inc. (NASDAQ:APPY) today. It was a stock I dissected just two days ago (on Tuesday - here's that chat), pointing out how all the telltale signs of bullishness were brewing. Sure enough, APPY popped on Wednesday, and as a result has gone from a mere potential big mover to an actual mover.
- [By Bryan Murphy]
If you're reading this, then odds are you know that Venaxis Inc. (NASDAQ:APPY) shares are up a solid 10% today, while the market as a whole is in the red. What you may not know about APPY, however, is that with today's strength, the stock has worked its way past a big hurdle and put itself into a situation where more upside is very likely.
- [By Lee Jackson]
Vernaxis Inc. (NASDAQ: APPY) is an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE MarkedAPPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis. They have moved ahead with their pivotal trial enrollment, and the analyst at Canaccord Genuity rates the company as a stock to buy. Its price target for the stock is a whopping $7, the high target for the stock. A move to that level would represent a 250% move for shareholders. The consensus target is at $5.25.�Vernaxis closed Friday at $1.97.
- [By Monica Gerson]
Venaxis (NASDAQ: APPY) soared 22.83% to $3.33 in the pre-market trading on positive top-line results from pivotal study of APPY1 test.
Plug Power (NASDAQ: PLUG) shares gained 11.18% to $7.56 in the pre-market after the company reported fourth-quarter results. Plug Power posted a quarterly loss of $0.08 per share, versus the estimated loss of $0.08 per share.
5 Best Quality Stocks To Own Right Now: Solazyme Inc (SZYM)
Solazyme, Inc. (Solazyme), incorporated on March 31, 2003, makes oil. The Company�� technology transforms a range of plant-based sugars into oils. Its renewable products can replace or enhance oils derived from the world�� three existing sources-petroleum, plants and animal fats. The Company is focused on commercializing its products into three target markets: fuels and chemicals, nutrition, and skin and personal care. In 2010, the Company launched its products, the Golden Chlorella line of dietary supplements. In March 2011, the Company launched its Algenist brand for the luxury skin care market through marketing and distribution arrangements with Sephora S.A. (Sephora International), Sephora USA, Inc. (Sephora USA), and QVC, Inc. (QVC).
The Company is engaged in development activities with multiple partners, including Chevron U.S.A. Inc., through its division Chevron Technology Ventures (Chevron), The Dow Chemical Company (Dow), Ecopetrol S.A. (Ecopetrol), Qantas Airways Limited (Qantas) and Conopoco, Inc., doing business as Unilever (Unilever).
In 2010, the Company entered into a 50/50 joint venture with Roquette Freres, S.A. (Roquette). In November 2010, the Company entered into a joint venture and operating agreement for Solazyme Roquette Nutritionals with Roquette. In December 2010, the Company entered into an exclusive distribution relationship with Sephora International, and in January 2011, the Company entered into a distribution relationship with Sephora USA. Under the arrangements, each of Sephora International and Sephora USA will distribute the Algenist product line in their respective territories.
In Fuels and Chemicals market its renewable oils can be refined and sold as drop-in replacements for marine, motor vehicle and jet fuels, as well as replacements for chemicals that are traditionally derived from petroleum or other conventional oils. The Company work with its refining partner Honeywell UOP to produce Soladiesel (renewable diesel), So! ladiesel renewable diesel for United States Naval vessels, and Solajet renewable jet fuel for both military and commercial application testing. In nutrition market the Company has developed microalgae-based food ingredients, including oils and powders that enhance the nutritional profile and functionality of food products while reducing costs for consumer packaged goods (CPG) companies. In Skin and Personal Care market the Company hs developed a portfolio of branded microalgae-based products. Its ingredient is Alguronic Acid, which the Company has formulated into a range of skin care products with anti-aging benefits. The Company is also developing algal oils as replacements for the oils used in skin and personal care products.
The Company competes with BP p.l.c., Royal Dutch Shell plc, and Exxon Mobil Corporation, jatropha, camelina, SALOV North America Corporation, Archer Daniels Midland Company, Cargill, Incorporated, DSM Food Specialties and Danisco A/S
Advisors' Opinion:- [By Maxx Chatsko]
Synthetic biology and renewable oils manufacturer�Solazyme� (NASDAQ: SZYM ) announced that it successfully conducted multiple initial fermentations in 500,000 liter fermentors in December 2012. While it was a big step forward in the right direction, I think the announcement was a bit premature. By "multiple," the company meant two and by "commercial scale production metrics," the company meant that only partial data had been collected. By reading SEC filings, investors can learn that the company has yet to prove microbial productivity at volumes greater than 128,000 liters. Not at all a nail in the coffin, but since the company believes it needs to reach 625,000 liter fermentors to be profitable, it is clear that engineers have plenty of work ahead of them.
Top Prefered Stocks To Buy Right Now: Enzymotec Ltd (ENZY)
Enzymotec Ltd., incorporated on March 08, 1998, is engaged in manufacturing of ingredients and medical foods company. Its technologies, research, and clinical validation process enables the Company to develop differentiated solutions across a variety of products. The Company markets its product portfolio primarily to established global consumer companies and target large and growing consumer health and wellness markets. Its clinically validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases. The Company operates in two segments: Nutrition and VAYA Pharma. In addition to its existing products, the Company has several other products to address additional indications in the development phase. enzyme processes; lipid modification; lipid analysis; and process technology and development.
Nutrition
The Company�� Nutrition segment develops and manufactures nutritional ingredient products based on lipids, such as phospholipids, which form the structural basis of cell membranes and are easily recognized, incorporated and used by the body. Its customer base for this segment includes formula and nutritional supplement companies such as Biostime and IVC. Its two selling nutritional ingredient products are InFat, a clinically-proven fat ingredient for infant formula, and krill oil. Its other products in this segment are targeted at improving brain health and providing benefits in memory, learning abilities and concentration.
VAYA Pharma
VAYA Pharma, develops, manufactures and sells branded, prescription-only medical foods for the dietary management of patients with certain medical conditions or diseases having special, medically determined nutrient requirements. Although medical foods must be safe and effective as demonstrated in human clinical studies, they do not require the same expensive and time consuming regulatory approval process typical of prescription drugs. In addition to! its existing products, it has several other products to address additional indications in the development phase.
Advisors' Opinion:- [By Victor Selva]
Finally, as opposed to what we just discussed, the firm is currently Zacks Rank # 4��ell, and it also has a longer-term recommendation of ��eutral�� A Sell rating indicates that the stock, over the next 1 to 3 months, will perform at an annualized rate of 4.8%, which is not attractive for investors. For investors looking for a Strong Buy Rank, BioLife Solutions, Inc. (BLFS) and Enzymotec Ltd. (ENZY) could be the options.
Top Prefered Stocks To Buy Right Now: PowerShares DWA Momentum Portfolio (PDP)
PowerShares DWA Technical Leaders Portfolio (Fund) seeks investment results that correspond generally to the price and of an equity index called the Dorsey Wright Technical Leaders Index (the Index). The Index consists of stocks of approximately 100 United States companies that are selected pursuant to a selection methodology of Dorsey Wright & Associates (the Index Provider). The Index is designed to identify companies that demonstrate powerful relative strength characteristics. Relative strength characteristics are based upon each security�� market performance. The companies are selected from a broad mid-cap and large-cap universe.
The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index is adjusted quarterly, and the Fund, using an indexing investment approach, attempts to replicate the performance of the Index. The Fund generally will invest in the stocks comprising the Index in proportion to their weightings in the Index. The Fund�� investment advisor is PowerShares Capital Management LLC.
Advisors' Opinion:- [By Victor Selva]
Of course, a great bet also involves many risks. Even though LCD technology became very popular in these last few years, both in TV screens and computer monitors, we should never miss the fact that technological markets are often exposed to products becoming obsolete due to the development of new, more efficient technology. Without going any further, it�� easy to recall the plasma display panel (PDP) fiasco, an apparently promising market in the 1990s and early 2000s but quickly replaced by LCDs (by 2008 LCDs sell 21.1 million units, almost 10 times PDP sales on the same year). Even Panasonic Corporation (PCRFF) announced it will interrupt production of PDP on 2014.
Top Prefered Stocks To Buy Right Now: Crestwood Midstream Partners LP (CMLP)
Crestwood Midstream Partners LP engages in gathering, compressing, treating, processing, and transporting natural gas primarily on the Barnett Shale formation of the Fort Worth Basin in north Texas. The company conducts its operations through its Cowtown System, Lake Arlington Dry System, and Alliance Midstream Assets, as well as the Fayetteville Shale and the Granite Wash plays. As of December 31, 2010, it managed approximately 500 miles of natural gas gathering pipelines. Crestwood Gas Services GP LLC serves as the general partner of Crestwood Midstream Partners LP. The company was formerly known as Quicksilver Gas Services LP and changed its name to Crestwood Midstream Partners LP in October 2010. Crestwood Midstream Partners LP was founded in 2004 and is based in Houston, Texas. Crestwood Midstream Partners LP is a subsidiary of Crestwood Gas Services Holdings LLC.
Advisors' Opinion:- [By Paul Ausick]
This deal follows three midstream transactions already this month. Regency Energy Partners LP (NYSE: RGP) will acquire PVR Partners LP (NYSE: PVR) for $5.6 billion, Crestwood Midstream LP (NASDAQ: CMLP) will acquire Arrow Midstream LLC for $750 million, and Buckeye Partners LP (NYSE: BPL) will pay $650 million to Hess Corp. (NYSE: HES) for 20 petroleum products terminals along the East Coast.
- [By Eric Volkman]
Crestwood Midstream Partners (NYSE: CMLP ) is boosting its presence in the West with a new acquisition. The company today announced it has reached agreement to purchase a 50% stake in Jackalope Gas Gathering Services from privately held RKI Exploration & Production. The price is roughly $108 million.
- [By Aimee Duffy]
With Kinder Morgan's acquisition of Copano Energy officially in the bag, all eyes are on the newest big deal in the midstream world: the merger of Crestwood Midstream Partners (NYSE: CMLP ) and Inergy (NYSE: CEQP ) . In this video, Fool.com contributor Aimee Duffy takes a look at this $7 billion deal, and explains what the ownership structure looks like at the new, yet-to-be-named entity.
No comments:
Post a Comment